Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Current Deferred Revenue: 2020-2024

Historic Current Deferred Revenue for Allogene Therapeutics (ALLO) over the last 3 years, with Mar 2024 value amounting to $86,000.

  • Allogene Therapeutics' Current Deferred Revenue changed negligibly% to $86,000 in Q1 2024 from the same period last year, while for Mar 2024 it was $86,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $86,000 for FY2023, which is 9.47% down from last year.
  • According to the latest figures from Q1 2024, Allogene Therapeutics' Current Deferred Revenue is $86,000, which was down 0.00% from $86,000 recorded in Q4 2023.
  • Over the past 5 years, Allogene Therapeutics' Current Deferred Revenue peaked at $39.0 million during Q4 2020, and registered a low of $86,000 during Q1 2023.
  • Its 3-year average for Current Deferred Revenue is $97,222, with a median of $86,000 in 2024.
  • Data for Allogene Therapeutics' Current Deferred Revenue shows a maximum YoY slumped of 99.60% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Allogene Therapeutics' Current Deferred Revenue stood at $39.0 million in 2020, then plummeted by 99.60% to $156,000 in 2021, then slumped by 39.10% to $95,000 in 2022, then declined by 9.47% to $86,000 in 2023, then remained steady at $86,000 in 2024.
  • Its Current Deferred Revenue stands at $86,000 for Q1 2024, versus $86,000 for Q4 2023 and $86,000 for Q3 2023.